We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Minimum Requirements for Reporting Fecal Microbiota Transplant Trial.
- Authors
Moossavi, Shirin; Bishehsari, Faraz; Ansari, Reza; Vahedi, Homayoon; Nasseri-Moghaddam, Siavosh; Merat, Shahin; Sobhani, Iradj; Keshavarzian, Ali; Malekzadeh, Reza
- Abstract
The article focuses on the minimum requirements for reporting fecal microbiota transplant (FMT) trial. FMT is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pseudomembranous colitis, which is caused by Clostridium difficile. About 15 trials have been conducted and published with results for the treatment of pseudomembranous colitis.
- Publication
Middle East Journal of Digestive Diseases, 2015, Vol 7, Issue 3, p177
- ISSN
2008-5230
- Publication type
Article